Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
McCann
Shaun R
SR
Gately
Kathy
K
Conneally
Eibhlin
E
Lawler
Mark
M
D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000628:therapy*; D010879:Piperazines / Q000008:administration & dosage* / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage* / Q000627:therapeutic use; D012333:RNA, Messenger / Q000032:analysis; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D014184:Transplantation, Homologous
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl